---
title: "EU GMP Annex 11 explained: computerized systems | Quantlix"
description: "EU GMP Annex 11 sets EU expectations for computerized systems in medicine manufacturing. See what it requires, the 2025 draft revision and its effect on software."
canonical: "https://quantlix.com/en/standards/eu-gmp-annex-11/"
last-updated: 2026-11-16
---

Source: https://quantlix.com/en/standards/eu-gmp-annex-11/
Language: en
Description: EU GMP Annex 11 sets EU expectations for computerized systems in medicine manufacturing. See what it requires, the 2025 draft revision and its effect on software.

**EU GMP Annex 11** [Quality and regulated operations](https://quantlix.com/en/standards/#quality)

# EU GMP Annex 11: computerized systems in medicine manufacturing

EU GMP Annex 11 is the European guideline for computerized systems used in GMP-regulated activities, covering risk management, suppliers, validation, data integrity, security and day-to-day operation.

[Discuss your project](https://quantlix.com/en/contact/) [Read the key points](https://quantlix.com/en/standards/eu-gmp-annex-11/#standard-overview)

## At a glance

**Full name**

EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice, Annex 11: Computerised Systems

**Published by**

European Commission (EudraLex Volume 4); the PIC/S GMP Guide carries a matching annex

**Type**

GMP guideline interpreting the GMP principles in EU law

**Current version**

Revision 1, January 2011, in operation since June 30, 2011; a revised draft was consulted on from July 7 to October 7, 2025 and was not final in November 2026

**Applies to**

Companies using computerized systems in GMP-regulated activities for human and veterinary medicinal products in the EU and EEA

**Last reviewed**

November 16, 2026 (2026-11-16)

## In plain terms

### Key points

- Annex 11 covers every computerized system used in GMP-regulated activities: applications are validated and IT infrastructure is qualified.
- Risk management decides the extent of validation and data integrity controls across the whole system lifecycle.
- It sets expectations for suppliers, data checks, audit trails, change control, periodic review, security, incidents, e-signatures and archiving.
- The 2011 text is in force. A revised Annex 11 was released as a draft in July 2025, with a revised Chapter 4 and a new draft Annex 22 on AI.

### What is EU GMP Annex 11?

EU GMP Annex 11 is **the European guideline for computerized systems used in good manufacturing practice (GMP)**. It is part of EudraLex Volume 4, the EU’s GMP guidelines for medicines, and applies to every computerized system used in a GMP-regulated activity, from a manufacturing execution system (MES) to a spreadsheet that calculates a release result.

Its starting principle is clear. When a computer replaces a manual operation, product quality, process control and quality assurance must not decline, and overall process risk must not increase. Applications are validated, and the IT infrastructure that runs them is qualified.

### What Annex 11 covers

The 2011 text has 17 short sections grouped into general, project and operational topics.

- **Risk management and people.** Risk management across the lifecycle sets the extent of validation and data integrity controls, and process owners, system owners, Qualified Persons and IT work together with defined roles.
- **Suppliers and service providers.** Formal agreements state the responsibilities of third parties that configure, integrate, host or maintain a system, and supplier audits are decided by risk.
- **Validation.** Lifecycle validation documentation, an up-to-date system inventory, user requirements traceable through the lifecycle and evidence of appropriate testing.
- **Data integrity in operation.** Built-in checks for data entered or exchanged, secure storage and backups, clear printouts and audit trails for GMP-relevant changes and deletions.
- **Control over time.** Change and configuration management, periodic evaluation, security, incident management and business continuity.
- **Signatures, release and archiving.** Electronic signatures, batch certification by a Qualified Person through the system and archived data that stays accessible and readable.

### Status of the revision

**The January 2011 revision, in operation since June 30, 2011, is the current text.** In July 2025, the European Commission and PIC/S (the Pharmaceutical Inspection Co-operation Scheme) published a draft revision for stakeholder consultation, open from July 7 to October 7, 2025. The draft, prepared by EMA’s GMP/GDP Inspectors Working Group with PIC/S, applies quality risk management at every step and tightens expectations on lifecycle control, supplier oversight, audit trails and security.

It was released with a revised Chapter 4 on documentation and a new draft Annex 22 on artificial intelligence, which covers how machine learning models are selected, trained, validated and overseen in GMP use. When we checked EudraLex Volume 4 in November 2026, none of the three had replaced the current texts. Systems should meet the 2011 Annex 11 today and be designed so the revision is easy to absorb.

### How it shows up in software projects

- **Inventory and risk assessment.** Each system is listed with its GMP functions, and a documented risk assessment sets the validation scope.
- **Requirements traceability.** User requirements link to design, configuration and test evidence, so every change shows what it touches.
- **Audit trails and review.** GMP-relevant changes and deletions are recorded with a reason, and audit trails are reviewed regularly as part of normal operation.
- **Agreements for cloud services.** Hosting and SaaS contracts define who handles backups, changes, access and incident reporting.
- **Periodic evaluation.** Systems are re-evaluated on a schedule to confirm they remain in a validated state, with findings tracked to closure.

### How we work with EU GMP Annex 11

We help [life sciences](https://quantlix.com/en/industries/life-sciences/) manufacturers build, integrate and modernize GMP systems, with Annex 11 expectations designed into the architecture, the delivery process and the evidence pack. Where you also supply the US market, we map the same controls to [21 CFR Part 11](https://quantlix.com/en/standards/21-cfr-part-11/), and we use the risk-based methods of [GAMP 5](https://quantlix.com/en/standards/gamp-5/). For AI features in manufacturing, we follow the draft Annex 22 and the [EU AI Act](https://quantlix.com/en/standards/eu-ai-act/) where they apply.

Validation is owned by the regulated company and assessed by GMP inspectors. Our role is to deliver systems and documentation that support that work, and a [technology assessment](https://quantlix.com/en/services/technology-assessment/) is often a good first step for an existing system landscape.

## Where it applies

Industries where this standard often shapes the work.

- ### [Pharmaceuticals & Life Sciences](https://quantlix.com/en/industries/life-sciences/)

  Research data, pharmaceutical operations and biotechnology platforms

## Related standards

[All standards](https://quantlix.com/en/standards/)

- 21 CFR Part 11

  ### [FDA electronic records and signatures](https://quantlix.com/en/standards/21-cfr-part-11/)

  21 CFR Part 11 is the FDA regulation that sets the conditions under which electronic records and electronic signatures are trusted as equivalent to paper records and handwritten signatures.
- GAMP 5

  ### [Risk-based GxP system validation](https://quantlix.com/en/standards/gamp-5/)

  GAMP 5 is the ISPE industry guide to a risk-based approach to compliant GxP computerized systems, used to plan specification, verification and lifecycle control for regulated software.
- EU AI Act

  ### [EU rules for artificial intelligence](https://quantlix.com/en/standards/eu-ai-act/)

  EU AI Act is the common name for Regulation (EU) 2024/1689, the EU law on artificial intelligence. It bans certain practices and sets duties for high-risk systems, general-purpose AI models and transparency.

## Services that support this work

The services we usually bring to projects that involve this standard.

[View all services](https://quantlix.com/en/services/)

### [Enterprise applications](https://quantlix.com/en/services/enterprise-applications/)

Quantlix designs and builds enterprise applications for internal workflows, business rules and system integration, with clear access controls and maintainable architecture.

### [Technology assessment](https://quantlix.com/en/services/technology-assessment/)

Assess operational workflows, data, integrations and AI readiness. Quantlix helps define a bounded Proving Ground and evidence for the next investment decision.

### [Cloud architecture](https://quantlix.com/en/services/cloud-architecture/)

Quantlix designs cloud infrastructure around workload requirements, security boundaries, operational visibility and cost, with an explicit path for deployment and recovery.

## Questions, answered

What teams usually ask us about this standard.

**Is EU GMP Annex 11 legally binding?**

Annex 11 is a guideline, but it interprets GMP principles that EU law makes mandatory for medicine manufacturers, and GMP inspectors assess companies against it. In practice, a GMP-regulated company is expected to follow it or show that its own approach gives the same level of control.

**What is the status of the Annex 11 revision?**

The European Commission and PIC/S consulted on a revised draft from July 7 to October 7, 2025, together with a revised Chapter 4 on documentation and a new Annex 22 on artificial intelligence. When we checked EudraLex in November 2026, the January 2011 Annex 11 was still the version in force.

**How does Annex 11 compare with 21 CFR Part 11?**

They overlap on audit trails, electronic signatures, access and record integrity. Annex 11 goes further on lifecycle topics, such as risk management, supplier agreements, periodic evaluation, incident management and business continuity, while Part 11 is a US regulation centered on electronic records and signatures.

**Does Annex 11 apply to cloud and SaaS systems?**

Yes. When a third party supplies, hosts or maintains a GMP computerized system, Annex 11 expects formal agreements that state the provider's responsibilities, and the need for a supplier audit is based on risk. Internal IT departments are treated in the same way.

**Does the draft Annex 22 allow generative AI?**

Not for critical uses. The 2025 draft applies to static models with deterministic outputs in critical GMP applications and says generative AI and large language models should not be used in critical GMP applications. In non-critical uses, qualified people stay responsible for the outputs.

## Official sources

Read the official text before relying on any detail. What applies to you depends on your role, your location and the version in force.

- [EudraLex Volume 4: EU GMP guidelines](https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en)
- [Consultation on Chapter 4, Annex 11 and Annex 22 (2025)](https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en)
- [Annex 11: Computerised Systems (2011 text)](https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf)

These guides explain each standard in plain terms. They are not legal advice, and they do not state that any product or organization conforms to a standard.

## Planning software around this standard?

Tell us which systems are involved and what you need to show. We will help you build the requirements in from the start.

[Discuss your project](https://quantlix.com/en/contact/)
